HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grandas, F. Articles by Obeso, J. A. Search for Related Content PubMed PubMed Citation Articles by Grandas, F. Articles by Obeso, J. A.

Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease

Movement Disorders Unit, Department of Neurology (Drs. Grandas, Lera, Rodriguez, and Obeso), Clinica Universitaria, University of Navarra, Pamplona, Spain, and the Department of Neurology (Drs. Gancher, Woodward, and Nutt), The Oregon Health Science University, Portland, OR.

Behavioral hyposensitivity to repeated apomorphine administration occurs in fluctuating parkinsonian patients. To determine to what extent the interval between doses influences the response, we administered equal paired apomorphine injections to 10 fluctuating parkinsonian patients. Subjects received two apomorphine injections at 2-hour and at 4-hour intervals on different days after a 10- to 12-hour overnight period without levodopa. Following apomorphine doses at 2-hour intervals, the duration of response was reduced by 40% (61 versus 42 minutes, p < 0.001) but was of equal duration when the doses were given at 4-hour intervals. These findings indicate that the interval between doses is a critical determinant of motor response. We postulate a time-dependent period of partial hyposensitivity to pulsatile DA stimulation.

Address correspondence and reprint requests to Dr. J.A. Obeso, Department of Neurology, Clinica Universitaria, Apdo. 192, 31080 Pamplona, Spain.

Presented in part at the 41st annual meeting of the American Academy of Neurology, Chicago, IL, April 1989.

Received September 11, 1991. Accepted for publication in final form December 11, 1991.

This article has been cited by other articles:

				A. G. Gulwadi, C. D. Korpinen, R. B. Mailman, D. E. Nichols, S.-Y. Sit, and M. T. Taber Dinapsoline: Characterization of a D1 Dopamine Receptor Agonist in a Rat Model of Parkinson's Disease J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 338 - 344. [Abstract] [Full Text]

				P. J. Blanchet, S. Konitsiotis, and T. N. Chase Motor Response to a Dopamine D3 Receptor Preferring Agonist Compared to Apomorphine in Levodopa-Primed 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Monkeys J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 794 - 794. [Abstract] [Full Text]